Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years

Susanna Esposito, Paola Marchisio, Samantha Bosis, Lara Lambertini, Laura Claut, Nadia Faelli, Ciro Bianchi, Giorgio L. Colombo, Nicola Principi

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

This paper reports the data concerning the net economic cost savings attributable to influenza vaccination in healthy children aged 2-5 years, and may be useful when deciding the best recommendations for the use of influenza vaccine in pediatrics. A total of 303 previously unprimed healthy children aged 2-5 years (163 males; mean age ± S.D.: 3.22 ± 2.43 years) were prospectively, blindly randomised in a 2:1 ratio to receive two doses of an inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland) or no vaccination. The results show that influenza vaccination of healthy children aged 2-5 years substantially reduces influenza-like illnesses and related costs in the children themselves and their families. However, larger and longer running study spanning multiple seasons may be warranted before suggesting the universal vaccination of this group of subjects.

Original languageEnglish
Pages (from-to)629-635
Number of pages7
JournalVaccine
Volume24
Issue number5
DOIs
Publication statusPublished - Jan 30 2006

Fingerprint

economic impact
influenza
Human Influenza
Vaccination
vaccination
Economics
Influenza Vaccines
Virosomes
Subunit Vaccines
Cost of Illness
Cost Savings
vaccines
Switzerland
economic costs
cost effectiveness
Pediatrics
dosage

Keywords

  • Children
  • Influenza
  • Influenza vaccination

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. / Esposito, Susanna; Marchisio, Paola; Bosis, Samantha; Lambertini, Lara; Claut, Laura; Faelli, Nadia; Bianchi, Ciro; Colombo, Giorgio L.; Principi, Nicola.

In: Vaccine, Vol. 24, No. 5, 30.01.2006, p. 629-635.

Research output: Contribution to journalArticle

Esposito, S, Marchisio, P, Bosis, S, Lambertini, L, Claut, L, Faelli, N, Bianchi, C, Colombo, GL & Principi, N 2006, 'Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years', Vaccine, vol. 24, no. 5, pp. 629-635. https://doi.org/10.1016/j.vaccine.2005.08.054
Esposito, Susanna ; Marchisio, Paola ; Bosis, Samantha ; Lambertini, Lara ; Claut, Laura ; Faelli, Nadia ; Bianchi, Ciro ; Colombo, Giorgio L. ; Principi, Nicola. / Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years. In: Vaccine. 2006 ; Vol. 24, No. 5. pp. 629-635.
@article{96907aa0aace45848266e74593aa9fd1,
title = "Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years",
abstract = "This paper reports the data concerning the net economic cost savings attributable to influenza vaccination in healthy children aged 2-5 years, and may be useful when deciding the best recommendations for the use of influenza vaccine in pediatrics. A total of 303 previously unprimed healthy children aged 2-5 years (163 males; mean age ± S.D.: 3.22 ± 2.43 years) were prospectively, blindly randomised in a 2:1 ratio to receive two doses of an inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland) or no vaccination. The results show that influenza vaccination of healthy children aged 2-5 years substantially reduces influenza-like illnesses and related costs in the children themselves and their families. However, larger and longer running study spanning multiple seasons may be warranted before suggesting the universal vaccination of this group of subjects.",
keywords = "Children, Influenza, Influenza vaccination",
author = "Susanna Esposito and Paola Marchisio and Samantha Bosis and Lara Lambertini and Laura Claut and Nadia Faelli and Ciro Bianchi and Colombo, {Giorgio L.} and Nicola Principi",
year = "2006",
month = "1",
day = "30",
doi = "10.1016/j.vaccine.2005.08.054",
language = "English",
volume = "24",
pages = "629--635",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "5",

}

TY - JOUR

T1 - Clinical and economic impact of influenza vaccination on healthy children aged 2-5 years

AU - Esposito, Susanna

AU - Marchisio, Paola

AU - Bosis, Samantha

AU - Lambertini, Lara

AU - Claut, Laura

AU - Faelli, Nadia

AU - Bianchi, Ciro

AU - Colombo, Giorgio L.

AU - Principi, Nicola

PY - 2006/1/30

Y1 - 2006/1/30

N2 - This paper reports the data concerning the net economic cost savings attributable to influenza vaccination in healthy children aged 2-5 years, and may be useful when deciding the best recommendations for the use of influenza vaccine in pediatrics. A total of 303 previously unprimed healthy children aged 2-5 years (163 males; mean age ± S.D.: 3.22 ± 2.43 years) were prospectively, blindly randomised in a 2:1 ratio to receive two doses of an inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland) or no vaccination. The results show that influenza vaccination of healthy children aged 2-5 years substantially reduces influenza-like illnesses and related costs in the children themselves and their families. However, larger and longer running study spanning multiple seasons may be warranted before suggesting the universal vaccination of this group of subjects.

AB - This paper reports the data concerning the net economic cost savings attributable to influenza vaccination in healthy children aged 2-5 years, and may be useful when deciding the best recommendations for the use of influenza vaccine in pediatrics. A total of 303 previously unprimed healthy children aged 2-5 years (163 males; mean age ± S.D.: 3.22 ± 2.43 years) were prospectively, blindly randomised in a 2:1 ratio to receive two doses of an inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland) or no vaccination. The results show that influenza vaccination of healthy children aged 2-5 years substantially reduces influenza-like illnesses and related costs in the children themselves and their families. However, larger and longer running study spanning multiple seasons may be warranted before suggesting the universal vaccination of this group of subjects.

KW - Children

KW - Influenza

KW - Influenza vaccination

UR - http://www.scopus.com/inward/record.url?scp=29544452975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29544452975&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.08.054

DO - 10.1016/j.vaccine.2005.08.054

M3 - Article

C2 - 16157429

AN - SCOPUS:29544452975

VL - 24

SP - 629

EP - 635

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 5

ER -